Whitehawk Therapeutics Inc
WHWKBuild a strategy around WHWK
Whitehawk Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- R&D spend of 86.3M TTM is 6x revenue (14.4M) - classic pre-commercial biotech burning cash on pipeline development.[Research and Development]
- Cash burn of 95M TTM against 38M cash leaves ~5 months runway without financing. Dilution imminent.[Free Cash Flow]
- Zero debt with 157M equity and P/B of 1.17x - trading near liquidation value despite pipeline optionality.[Price to Book Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 25M or financing announced — Financing terms will determine dilution magnitude and signal market confidence in pipeline.
- Research and Development: Quarterly R&D drops >20% from 21.5M/quarter run rate — R&D cuts signal pipeline prioritization or funding constraints - thesis-changing either way.
- Total Revenue: Quarterly revenue exceeds 5M (vs 3.6M run rate) — Revenue inflection would extend runway and improve financing leverage.
Bull Case
Trading at 1.17x book with zero debt provides downside floor near tangible asset value of 157M while retaining pipeline upside.
89% gross margin TTM on 14.4M revenue suggests viable commercial model if pipeline succeeds - margin structure intact.
Bear Case
5-month cash runway with -96M FCF makes dilutive financing near-certain; current shareholders face 30-50% dilution risk.
Revenue collapsed 41% YoY while OpEx at 121M dwarfs sales - no path to profitability without transformative clinical success.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage WHWK's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Capital raise required within 6 months; terms will define equity value trajectory.
- 38M cash vs 95M annual burn = 5-month runway
- No debt capacity to bridge gap
- Pipeline milestones may improve financing terms
Valuation Context
Caveats
Public Strategies Rankings
See how Whitehawk Therapeutics Inc ranks across different investment strategies.
Leverage WHWK's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
WHWK Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$234.9M | — | ||
$197.34M | — | ||
0.00 | — | ||
$7.14M | -72.5% | — | |
$-0.33 | — | ||
-1,601% | -1351.6% | — | |
-288% | -43.1% | — | |
$-97.98M | — | ||
-21.8% | +59.0% | — | |
Beta 5Y (Monthly) | unknown | — |
WHWK Dividend History
WHWK Stock Splits
WHWK SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/12/26 | 12/31/25 | 10-K | |
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
03/28/25 | 12/31/24 | 10-K | |
11/06/24 | 09/30/24 | 10-Q | |
08/07/24 | 06/30/24 | 10-Q | |
05/08/24 | 03/31/24 | 10-Q | |
03/13/24 | 12/31/23 | 10-K | |
11/08/23 | 09/30/23 | 10-Q | |
08/09/23 | 06/30/23 | 10-Q | |
05/10/23 | 03/31/23 | 10-Q | |
03/29/23 | 12/31/22 | 10-K | |
11/09/22 | 09/30/22 | 10-Q | |
08/10/22 | 06/30/22 | 10-Q | |
05/12/22 | 03/31/22 | 10-Q | |
03/17/22 | 12/31/21 | 10-K | |
11/10/21 | 09/30/21 | 10-Q | |
08/10/22 | 06/30/21 | 10-Q | |
05/12/22 | 03/31/21 | 10-Q | |
03/17/22 | 12/31/20 | 10-K | |
11/10/21 | 09/30/20 | 10-Q |